University of Minnesota researchers have identified the mechanism of a potential HIV drug target, which could be more cost-effective than currently used HIV drugs.
The study expanded upon previous UMN research, which identified that the nucleoside 5-azacytidine (5-aza-C) blocked HIV’s ability to spread. 5-aza-C triggers lethal mutagenesis, a process in which HIV mutations speed up to a point that the HIV essentially wears itself out.
Were drug design a road, it would surely be a Minnesota street fraught with potholes, ice and gravel.
Even the best ideas can fall by the wayside somewhere between the lab and your corner pharmacy in the process of drug discovery and development.
Recently, University of Minnesota Center for Drug Design member, organic chemist and assistant professor Liqiang Chen, Ph.D., published a paper in the Journal of Medicinal Chemistry outlining the discovery of a potent and selective protein-inhibitor. Blocking the protein, Sirtuin 2 (SIRT2), also has the potential to block a primary contributor to Parkinson’s disease from causing harm.
A new compound in development at the University of Minnesota shows promise as a breakthrough drug for treating chronic pain.
The new compound, developed by Philip Portoghese, Ph.D., of the University of Minnesota’s College of Pharmacy, appears to be the first of its kind. A patent has been applied for, and the University’s Center for Translational Medicine has been conducting proof-of-concept studies. As a potential medication, the compound offers benefits lacked by current medications: It does not induce the body to develop tolerance or dependence, as opioid painkillers do. It is more potent than other opioid pain medications. It reduces and inhibits neuropathic pain, post-operative pain, burn pain, spinal injury pain and inflammation.
University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.
Complete findings are printed in today’s issue of The Journal of Virology.
The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis.